Decision making in the pharmacological management of cardiac and renal diseases in dogs and cats requires multiple factors to be taken into account to achieve the desired therapeutic outcome. Eight international experts will present the most recent evidence on which these decisions can be made and is tailored to general practitioners with a keen interest in Ecardiovascular and renal therapeutics.
Evidence-based and practically orientated reviews will provide practitioners with the most up-to-date evidence on which therapeutic decision making can be based, and will be supported by a series of interactive case presentations to illustrate the decision-making process that can directly be implemented in clinical practice. n addition, the symposium is forward-looking predicting the use of two new groups of therapeutic agents (SGLT2-inhibitors and HIF prolyl hydroxylase inhibitors) in veterinary medicine. The SGLT2 inhibitors appear to have beneficial effects in both cardiac and renal patients and the HIF prolyl hydroxylase inhibitors are a novel approach to the management of anaemia associated with chronic kidney disease.